Previous 10 | Next 10 |
2023-09-06 10:21:15 ET More on AbbVie, Novartis, etc. AbbVie: Proving The Bears Wrong Again As Shares Surged AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued AbbVie: Balance Is Everything AbbVie: Still A Buy According To Buffett's 10xEBT Rule A...
2023-09-05 10:15:00 ET In mid-August, Novartis (NYSE: NVS) shared positive results from the phase 3 clinical trial of its biosimilar to Regeneron (NASDAQ: REGN) and Bayer AG 's (OTC: BAYR.Y) Eylea. The Swiss drugmaker's results from the phase 3 clinical trial of its ...
2023-09-05 08:27:58 ET Summary Biogen receives FDA approval for Leqembi, a treatment for Alzheimer's Disease, providing a large market opportunity. Biogen's acquisition of Reata Pharmaceuticals brings the potential for significant sales growth with SKYCLARYS, a drug for Friedreich...
2023-09-03 12:00:00 ET More on Medicare pricing negotiations Wall Street lists potential targets for Medicare drug price negotiations Analysts rule out major industry impact from drug pricing negotiations J&J, Merck, Regeneron most exposed to Medicare drug price ...
2023-09-02 14:00:00 ET More on pharma companies Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad? Novo Nordisk: Super Focused Pharma Company For The Long Run Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rati...
2023-08-31 15:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-08-29 07:45:20 ET The Centers for Medicare and Medicaid Services (CMS) announced on Tuesday the first 10 Medicare Part D drugs it selected for pricing negotiations, a provision introduced as part of last year's Inflation Reduction Act. The list includes Eliquis , a blood thinne...
2023-08-24 19:15:17 ET More on Biogen Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects Biogen Inc. ( BIIB ) Q2 2023 Earnings Call Transcript Biogen And Alzheimer's Disease: Too Early To Celebrate Will Watershed Moment For ...
2023-08-24 14:12:04 ET More on generic drugmakers Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain Novartis schedules Sandoz...
2023-08-24 09:44:18 ET The Biden administration is expected to announce the first 10 drugs that will be subject to Medicare price negotiations on Tuesday before the markets open, Politico reported, citing people familiar with the plans. The move, introduced as part of last year ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...